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A B S T R A C T
Some oxysterols are precursors of bile acid synthesis and play an important role in cholesterol
homeostasis. However, if they are involved in the pathogeny of genetic hypercholesterolemia has not
been previously explored. We have studied non-cholesterol sterol markers of cholesterol synthesis
(lanosterol and desmosterol) and oxysterols (7a-hydroxy-4-cholesten-3-one, 24S-hydroxycholesterol
and 27-hydroxycholesterol) in 200 affected subjects with primary hypercholesterolemia of genetic
origin, negative for mutations in LDLR, APOB, PCSK9 and APOE genes (non-FH GH) and 100 normolipemic
controls. All studied oxysterols and cholesterol synthesis markers were significantly higher in affected
subjects than controls (P < 0.001). Ratios of oxysterols to total cholesterol were higher in non-FH GH than
in controls, although only 24S-hydroxycholesterol showed statistical significance (P < 0.001). Cholesterol
synthesis markers had a positive correlation with BMI, triglycerides, cholesterol and apoB in control
population. However, these correlations disappeared in non-FH GH with the exception of a weak positive
correlation for non-HDL cholesterol and apoB. The same pattern was observed for oxysterols with high
positive correlation in controls and absence of correlation for non-FH GH, except non-HDL cholesterol for
24S-hydroxycholesterol and 27-hydroxycholesterol and apoB for 27-hydroxycholesterol. All non-
cholesterol sterols had positive correlation among them in patients and in controls. A total of 65 (32.5%)
and 35 (17.5%) affected subjects presented values of oxysterols ratios to total cholesterol above the 95th
percentile of the normal distribution (24S-hydroxycholesterol and 27-hydroxycholesterol, respectively).
Those patients with the highest levels of 24S-hydroxycholesterol associated an increase in the carotid
intima media thickness. These results suggest that bile acid metabolism is affected in some patients with
primary hypercholesterolemia of genetic origin, negative for mutations in the candidate genes, and may
confer a higher cardiovascular risk. Our results confirm that cholesterol synthesis overproduction is a
primary defect in non-HF GH and suggest that subjects with non-FH GH show high levels of oxysterols in
response to hepatic overproduction of cholesterol.
ã 2016 Elsevier Ltd. All rights reserved.
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Autosomal dominant hypercholesterolemias (ADH) are charac-
terized by high levels of low-density lipoprotein (LDL) cholesterol,
familial presentation and high risk of premature cardiovascular
disease [1]. Most ADH has familial hypercholesterolemia (FH) due
to mutations in the LDLR gene that encodes for the LDL receptor [2].
Approximately 2–15% of ADH subjects have familial defective
apolipoprotein B-100 (FDB) due to mutations in the LDL receptor-
binding domain coding region of the APOB gene, which encodes for
apolipoprotein B-100 [3], or mutations in proprotein convertase
subtilisin/kexin type 9 gene (PCSK9), a protein involved in the LDL
receptor recycling [4]. Recently, a mutation in APOE (p.Leu167del)
has also been associated with ADH [5,6]. Patients with mutations in
these genes present an indistinguishable phenotype and are now
included in the FH definition [2]. The genetic cause and pathogenic
mechanism of approximately 20–40% of ADH are unknown [7,8],
and probably they are a heterogeneous group of diseases including
some severe polygenic hypercholesterolemias [9]. For this reason,
we named them as non-FH genetic hypercholesterolemias (non-FH
GH).
Cholesterol homeostasis is achieved through a highly sophisti-
cated regulation of the uptake, synthesis, esterification and biliary
excretion of cholesterol and its derivatives in the body [10].
Oxysterols are oxygenated derivatives of cholesterol that are
important as intermediates or end products in cholesterol
excretion pathways. The rapid degradation and excretion of
oxysterols are facilitated by their physical properties, allowing
them to go across lipophilic membranes and to be redistributed in
the cell at a much faster rate than cholesterol itself. Important roles
with cholesterol turnover, atherosclerosis, apoptosis, necrosis,
inflammation, immunosuppression, and the development of
gallstones have been described for oxysterols [11–14]. Importantly,
oxysterols mediate on cholesterol metabolism to bile acids. The
liver nuclear X receptors (LXRs), the liver receptor homologue
(LRH) and the hepatocyte nuclear factor (HNF4a) have the ability
to bind oxysterols with high affinity [15,16] to produce and secrete
bile acids in mice [17]. Important oxysterol ligands for these
receptors include: 24S-, 25- and 27- hydroxycholesterol [18] and
3b-hydroxy-5-cholestenoic acid [19].
The classical and quantitatively most important pathway for
bile acid synthesis starts with a 7a-hydroxylation of cholesterol via
the rate-limiting hepatic cytochrome P-450 enzyme, cholesterol
7a-hydroxylase (CYP7A1) [20]. In addition to the 7a-hydroxylase
pathway, there is a bile acid synthesis alternative pathway, starting
with the introduction of a hydroxyl group at the terminal methyl
group (C27 position) of the steroid side chain [20]. The first step
involves the oxidation of cholesterol to 27-hydroxycholesterol by
CYP27A1, which is subsequently hydroxylated by oxysterol
7a-hydroxylase (CYP7B1). It has been calculated that 5%–10% ofPlease cite this article in press as: L. Baila-Rueda, et al., Bile acid synthesi
for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and caroti
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extrahepatic 27-hydroxylation [21,22]. Another alternative path-
way for bile acid synthesis is through oxidation of cholesterol to 24
(S)-hydroxycholesterol. Cholesterol 24-hydroxylase (CYP46A1) is
expressed mainly in the brain. There is no synthesis of 24S-
hydroxycholesterol from the human liver, hence is a bile acids
precursor not related with the hepatic cholesterol synthesis [23].
Pullinger et al. described a non-FH GH kindred carring a loss-of-
function mutation in the CYP7A1 gene, encoding the cholesterol
7a-hydroxylase enzyme, which catalyzes the initial step in
cholesterol catabolism and bile acid synthesis. The mutation led
to high levels of LDL cholesterol, markedly deficient rate of bile acid
excretion, and upregulation of the alternative bile acid pathway
[24]. However, the CYP7A1 gene has not been further associated
with FH neither in linkage analysis [25] nor whole exome
sequencing of patients without LDLR/APOB/PCSK9 mutations
[26]. Currently, the effect on lipids that can be expected from
the accumulation or deficiency of the intermediate metabolites of
bile acid synthesis is not clear [18], and it has not been explored so
far in subjects with non-FH GH. Given that bile acid formation is a
key metabolic pathway, that the association between oxysterols
and cholesterol concentration in humans [27] and that a family
with a genetic defect in bile acid formation has been described as a
cause of genetic hypercholesterolemia [24], we hypothesized that
bile acid precursors could be markers of some forms of non-FH GH.
In order to better characterize the metabolic abnormalities
associated with non-FH GH, we have studied non-cholesterol
sterol markers of cholesterol and bile acid hepatic synthesis in a
large group of subjects with non-FH GH and normolipemic
controls, in which major confounding factors for plasma non-
cholesterol sterols were studied. In addition, the non cholesterol
sterol profile was analyzed with a sensitive and reliable method by




Selected subjects (n = 200) were unrelated adults 18–79 years of
age with the clinical diagnosis of ADH: LDL cholesterol above the
95th percentile of the Spanish population [29], triglycerides below
200 mg/dL, primary cause and familial presentation (at least one
first-degree relative with the same phenotype) from the Lipid
Clinic at Hospital Universitario Miguel Servet, Zaragoza, Spain. In
all subjects, the presence of functional mutations in LDLR, APOB
and PCSK9, and p.Leu167del in APOE were ruled out as described
below. Secondary causes of hypercholesterolemia including:
obesity (body mass index >30 kg/m2), poorly controlled type 2
diabetes (HbA1c >8%), renal disease with glomerular filtration rates precursors in subjects with genetic hypercholesterolemia negative
d atherosclerosis, J. Steroid Biochem. Mol. Biol. (2016), http://dx.doi.
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upper normal limit), hypothyroidism (TSH >6 mIU/L), pregnancy,
autoimmune diseases and protease inhibitors were exclusion
criteria. Subjects disclosing APOE e2/e2 genotype were not
considered for this study. Subjects with previous cardiovascular
disease or high risk for cardiovascular disease (>20% in the next 10
years) were excluded except if they were not on lipid-lowering
drugs. Cardiovascular risk factors assessment, personal and family
history of cardiovascular disease, consumption of drugs affecting
intestinal or lipid metabolism and anthropometric measurements
were performed in all participants. The normolipemic group
consisted of healthy, unrelated men and women volunteers aged
18–79 years, who underwent a medical examination at the
Hospital Miguel Servet of Zaragoza. Exclusion criteria for control
subjects were personal or parental history of premature cardio-
vascular disease or dyslipidemia, current acute illness, or use of
drugs that might influence glucose or lipid metabolism. All
subjects signed informed consent to a protocol previously
approved by our local ethical committee (Comité Ético de
Investigación Clínica de Aragón, Zaragoza, Spain).
2.2. Blood analyses
Fasting blood for biochemical profiles was drawn after at least
5–6 weeks without hypolipidemic drug treatment, plant sterols or
fish oil supplements. Cholesterol and triglycerides were deter-
mined by standard enzymatic methods. HDL cholesterol was
measured by a precipitation technique. Apo A1, apo B, lipoprotein
(a) and C-reactive protein (CRP) were determined by nephelometry
using IMMAGE-Immunochemistry System (Beckman Coulter).Table 1
Clinical and biochemical characteristics in non-FH GH patients and normolipidemic co
Non-FH GH
(n = 200)
Female, n (%) 100 (50) 
Age, years 45.2  11.7 
Current Smokers, n (%) 50 (25) 
Former Smokers, n (%) 58 (29) 
Non Smokers, n (%) 92 (46) 
Apolipoprotein E, n (%) 
E3/3 133 (66.5) 
E3/4 54 (71.8) 
E3/2 3 (1.5) 
E4/4 9 (4.5) 
E2/4 1 (0.5) 
Systolic Blood Pressure, mm Hg 127  17 
Diastolic Blood Pressure, mm Hg 80 (71–90) 
Body Mass Index, kg/m2 25.3  3.5 
Weight, kg 70.0  12.6 
Waist Circumference, cm 86.8  10.7 
Cholesterol enzymatic method, mg/dL 295  44 
Cholesterol HPLC–MS/MS, mg/dL 282  62 
Triglycerides, mg/dL 109  38 
HDL Cholesterol, mg/dL 59  16 
Non HDL cholesterol, mg/dL 236  43 
LDL Cholesterol, mg/dL 213  42 
Apolipoprotein A1, mg/dL 162  32 
Apolipoprotein B, mg/dL 150  29 
Lipoprotein (a), mg/dL 24 (11–56) 
C-Reactive Protein, mg/dL 1.6 (0.5–2.7) 
Glucose, mg/dL 88 (82–96) 
Gamma-glutamyl transpeptidase, U/L 22.0 (14.5–29.5) 
Glutamic-pyruvic transaminase, U/L 21.0 (17.0–40.0) 
Mean common carotid IMT, mm 0.696  0.153 
Mean carotid IMT, mm 0.749  0.156 
*Values are mean  SD or median (interquartile range). #P refers to differences calculat
skewed data.
HDL denotes high density lipoprotein; LDL, low density lipoprotein; HPLC, high-perfor
Please cite this article in press as: L. Baila-Rueda, et al., Bile acid synthesi
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secretion
Serum oxysterols (7a-hydroxy-4-cholesten-3-one, 24S-
hydroxycholesterol and 27-hydroxycholesterol), precursors of
different pathways of bile acid synthesis and serum cholesterol
synthesis markers (desmosterol and lanosterol) were quantified
after 10 h of fasting. Serum concentration of cholesterol,
7a-hydroxy-4-cholesten-3-one, 24S-hydroxycholesterol, 27-
hydroxycholesterol, desmosterol and lanosterol were quantified
using HPLC–MS/MS according to the method previously described
[28], and were expressed as mg/dL as well as normalized to mg/dL
of total cholesterol. Briefly, 100 ml of serum were transferred to a
screw-capped vial and deuterium-labelled internal standard, [2H6]
cholesterol-26,26,26,27,27,27, (7.9 mM), was added to determine
non-cholesterol sterols. Another 100 ml of serum were transferred
to a screw-capped vial, deuterium-labelled internal standard,
[2H7] cholesterol-25,26,26,26,27,27,27, was added to determine
cholesterol.
For the hydrolysis of non-cholesterol sterols, the serum samples
were first subjected to saponfication. After the addition of 1 ml of
freshly prepared 0.71 M ethanolic sodium hydroxide, alkaline
hydrolysis was performed for 20 min at 60 C in an ultrasound bath.
Hydrolysis reagents were prepared immediately prior to use.
Thereafter, 500 ml of deionized water were added. The sample was
extracted twice with 3 ml of hexane. The extract was dried at 30 C
under a stream of nitrogen and reconstituted in 200 ml methanol.
This extract was loaded onto the SPE cartridge. The C18 cartridges
used for the SPE extraction (100 mg, Discovery DSC-18, Supelco,















126  22 0.588
80 (72–87) 0.955
25.8  5.1 0.407
72.0  15.0 0.232
88.7  13.5 0.240
198  31 <0.001
192  46 <0.001
83.3  37 <0.001
54  13 0.004
142  36 <0.001
128  26 <0.001
159  29 0.404






0.693  0.144 0.881
0.705  0.147 0.048
ed by Student’s t-test for data normally distributed and Mann–Whitney U test for
mance liquid chromatography; MS, mass spectrometry
s precursors in subjects with genetic hypercholesterolemia negative
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propanol by gravity and 40 ml of the final mixture were injected
into the HPLC–MS/MS system.
2.4. Genetic analysis
DNA was isolated from EDTA blood samples following
standard protocols. APOE sequencing was performed in all study
subjects as previously described [30]. Large rearrangements in the
LDLR gene were analyzed using a method based on quantitative
fluorescent multiplex PCR. Brieftly, the method involves two PCR
reactions; the first amplifies the selected exons using primer
sequences tagged with universal primers, while the second
amplifies the first amplicons using the universal primers. One
of the second PCR reaction universal primers is labelled with a
fluorescent dye which is incorporated into the PCR products which
are then electrophoresed on the DNA sequencer. The relative
amounts of the amplified peak areas are determined and
compared to ratios obtained for DNA from normal controls [31].
The screening for LDLR and APOB mutations was carried out using
Lipochip Platform (Progenika Biopharma S. A., Bilbao, Spain). The
platform consists of two consecutive steps: the first one is the
LIPOchip1 microarray analysis for the detection of the most
frequent Spanish point mutations in the LDLR gene and in the APOB
exon 26, as well as CNVs in LDLR. When the LIPOchip1 microarray
gives a negative result (no mutation is found), the LDLR, APOB
(binding domain) and PCSK9 gene coding sequences, exon-intron
boundaries, and short proximal intronic sequences were se-
quenced with a GS Junior system (Roche Diagnostics Corporation,
Basel, Switzerland) [32].
2.5. Ultrasonographic evaluation
Ultrasonographic evaluation for measurement of carotid intima
media thickness (IMT) was performed according to standardized
scan- and image analysis protocols, as has been previously
described [33]. In brief, we bilaterally assessed carotid IMT of
the posterior walls of distal centimeter of the arterial segments
proximal to the carotid dilatation, the common carotid arterial
segment (CC), the segment, between the dilatation and the flow
divider, the carotid bulb (CB) and the internal carotid (IC). Images
were collected with an Acuson Sequoia 512 ultrasound scanner
equipped with an 8L5 transducer (Siemens AG, Erlangen,
Germany) of each arterial segment. Of every carotid arterial
segment, the mean (average) IMT value of the arterial wall
segment was obtained. The per subject aggregate of the right and
left CC (mean common carotid IMT), CB and IC mean IMT values
were used for calculating subject mean IMT aggregate (mean
carotid IMT).Table 2
Non-cholesterol sterols in non-FH GH patients and normolipidemic controls.*
Non-FH GH
(n = 200)
Desmosterol mg/dL 0.70 (0.54–0.90) 
Lanosterol mg/dL  102 0.033 (0.025–0.045) 
27-hydroxycholesterol mg/dL  102 1.54 (1.12–2.04) 
24S-hydroxycholesterol mg/dL  102 0.98 (0.71–1.17) 
7a-hydroxycholestenona mg/dL  102 0.26 (0.17–0.40) 
Desmosterol to-TC  103 2.44 (1.79–3.60) 
Lanosterol to-TC  103 0.111 (0.081–0.186) 
24S-hydroxycholesterol to-TC  103 0.033 (0.024–0.048) 
27-hydroxycholesterol to-TC  103 0.054 (0.037–0.080) 
7a-hydroxycholestenona to-TC  103 0.0092 (0.0059–0.016
*Values are mean  SD or median (interquartile range). #P refers to differences calculat
skewed data.
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Comparison of lipid variables among groups was performed
using the Student’s t-test for data normally distributed and
Mann–Whitney U test for skewed data. When significant differ-
ences were detected, multiple comparisons were made by using
the Bonferroni correction for normally distributed variables. The
significance was set at P < 0.05 for the variables. Non-cholesterol
sterol to cholesterol ratios were log transformed to achieve
variance homogeneity. Data are presented as mean and standard
deviation (SD) for continuous variables. All statistical analyses
were performed with SPSS software (version 15.0; SPSS, Chicago,
IL, USA).
3. Results
3.1. Main clinical and biochemical characteristics
The main clinical and biochemical characteristics of 200 non-FH
GH patients and 100 normolipemic controls are presented in
Table 1. Non-FH GH participants had statistically significant higher
values of total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a),
apoB and mean carotid IMT than normolipemic controls. No
differences in age, BMI, weight and waist circumference were
found between patients and controls. Oxysterols (24S-hydrox-
ycholesterol and 27-hydroxycholesterol) and cholesterol synthesis
precursors (lanosterol and desmosterol) were significantly higher
in non-FH GH than in controls (P < 0.001). Ratios of oxysterols to
total cholesterol were higher in non-FH GH than in normolipemic
controls, although only 24S-hydroxycholesterol showed statistical
significance (P < 0.001) (Table 2).
3.2. Spearman’s rank correlations in non-FH GH patients and in
normolipemic controls
Spearman’s rank correlations in non-FH GH patients and in
normolipemic controls are reported in Table 3 and supplemental
figure. As expected, desmosterol and lanosterol, markers of
cholesterol synthesis, had a positive correlation with BMI,
triglycerides, cholesterol and apoB in control population. However,
these positive correlations disappeared in non-FH GH with the
exception of a weak positive correlation for non-HDL cholesterol
and apoB. The same pattern was observed for bile acid precursors
with high positive correlation in controls and absence of
correlation for non-FH GH, except non-HDL cholesterol for
24S-hydroxycholesterol and 27-hydroxycholesterol and apoB for
27-hydroxycholesterol.
Spearman’s rank correlations of non-cholesterol sterols in non-












) 0.0071 (0.0043–0.014) 0.069
ed by Student’s t-test for data normally distributed and Mann–Whitney U test for
s precursors in subjects with genetic hypercholesterolemia negative
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Table 3
Spearman’s correlation coefficients of non-cholesterol sterols and lipids in non-FH GH patients and normolipidemic controls.* denotes stadistical significance.
Body mass Index Triglycerides HDL-cholesterol HDL non-cholesterol Apolipoprotein B
r P r P r P r P r P
Desmosterol Controls 0.295* 0.004 0.545* <0.001 0.162 0.116 0.526* <0.001 0.611* <0.001
Non-FH GH 0.012 0.862 0.072 0.307 0.043 0.540 0.217* 0.002 0.115 0.108
Lanosterol Controls 0.295* 0.004 0.446* <0.001 0.132 0.201 0.460* <0.001 0.571* <0.001
Non-FH GH 0.055 0.440 0.050 0.478 0.001 0.989 0.200* 0.004 0.163* 0.022
24S-hydroxycholesterol Controls 0.162 0.119 0.524* <0.001 0115 0.266 0.358* <0.001 0.482* <0.001
Non-FH GH 0.101 0.153 0.002 0.981 0.060 0.396 0.188* 0.007 0.130 0.067
27-hydroxycholesterol Controls 0.347* 0.001 0.579* <0.001 0.234* 0.022 0.461* <0.001 0.588* <0.001
Non-FH GH 0.013 0.855 0.1122 0.083 0.129 0.066 0.291* <0.001 0.310* <0.001
7a-hydroxycholestenona Controls 0.259* 0.012 0.339* 0.001 0.162 0.117 0.095 0.353 0.069 0.513
Non-FH GH 0.011 0.873 0.096 0.177 0.120 0.090 0.026 0.712 0.043 0.545
Table 4
Spearman’s correlation coefficients of non-cholesterol sterols in non-FH GH patients and normolipidemic controls.* denotes stadistical significance.
Lanosterol 24S-hydroxycholesterol 27-hydroxycholesterol 7a-hydroxycholestenona
p p p p p p p p
Desmosterol Controls 0.884* <0.001 0.699* 0.001 0.809* <0.001 0.209* 0.050
Non-FH GH 0.789* <0.001 0.757* <0.001 0.756* <0.001 0.417* <0.001
Lanosterol Controls – – 0.689* <0.001 0.785* <0.001 0.236* <0.001
Non-FH GH – – 0.669* <0.001 0.634* <0.001 0.342* <0.001
24S-hydroxycholesterol Controls – – – – 0.738* <0.001 0.135 0.181
Non-FH GH – – – – 0.743* <0.001 0.450* <0.001
27-hydroxycholesterol Controls – – – – – – 0.262* <0.001
Non-FH GH – – – – – – 0.431* <0.001
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them in patients and in controls. This correlation was high between
cholesterol synthesis markers and 24S-hydroxycholesterol and
27-hydroxycholesterol, and weak, although significant, with 7a-
hydroxy-3-cholesten-4-one except for 24S-hydroxycholesterol.
3.3. Population distribution depending on oxysterols and cholesterol
synthesis markers
Fig. 1 shows the distribution of 24S-hydroxycholesterol,
27-hydroxycholesterol, desmosterol and lanosterol in non-FH
GH and in controls. Distribution of these oxysterols in non-FH
GH indicated a group of subjects with higher values of both
oxysterols compared with the control population. The distribution
of 7a-hydroxy-3-cholesten-4-one did not show differences
between patients and controls.
3.4. Clinical characteristics and subclinical atherosclerosis in non-FH
GH patients according to the 24S-hydroxycholesterol and 27-
hydroxycholesterol ratios to TC
Clinical characteristics and subclinical atherosclerosis in non-
FH GH patients according to the 24S-hydroxycholesterol and
27-hydroxycholesterol ratios to TC are presented in Table 5. There
was a trend to higher carotid IMT and statistical significance was
reached for mean common carotid IMT in subjects with
24S-hydrocholesterol ratio to TC over the 95th percentile of the
control population. The clinical characteristics, BMI and apoB were
significantly lower in cases with 24S-hydroxycholesterol ratio toTC
over the 95th percentile of the control population. Cholesterol
synthesis precursors and oxysterols showed higher concentrations
when 24S-hydroxycholesterol and 27-hydroxycholesterol were
over the 95th percentile, P < 0.001.Please cite this article in press as: L. Baila-Rueda, et al., Bile acid synthesi
for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and caroti
org/10.1016/j.jsbmb.2016.10.0034. Discussion
Serum non-cholesterol sterol analysis is a useful method for the
evaluation of cholesterol metabolism and a well accepted method
for the diagnosis of many inherited disorders in its metabolism in
humans [34]. Plasma levels of the cholesterol precursors, as
desmosterol or lanosterol, served as markers of cholesterol
synthesis [34,35], whereas 7a-hydroxy-3-cholesten-4-one and
24S-hydroxycholesterol and 27-hydroxycholesterol served as
precursors of bile acid synthesis in the classic and in the alternative
pathway, respectively [36].
This is the first study, to our knowledge, to analyze the bile acid
synthesis precursors in a large number of well-clinically defined
subjects with non-FH GH. Our study shows that many subjects
with non-FH GH show an increase in their concentrations of bile
acid synthesis precursors and cholesterol synthesis markers. When
oxysterols concentrations were adjusted by total cholesterol levels,
this increase was only observed for 24S-hydroxycholesterol.
Although there is a large variation and heterogeneity in oxysterols
concentration, a very high percentage of subjects had a
27-hydroxycholesterol and 24S-hydroxycholesterol concentration
above the 95th percentile of the values of a normolipemic
population, suggesting that non-FH GH is heterogeneous and that
bile acid metabolism could be involved in the pathogenesis of
some of these patients.
The serum concentration of oxysterols depends on the balance
between their production and hepatic metabolism. 24S-hydrox-
ycholesterol is mainly produced in cerebral tissue in humans and
this cerebral production remains fairly constant in adults. Hence,
its plasma concentrations are mainly modified by hepatic
metabolism. The higher concentration of 24S-hydroxycholesterol
in our study suggests that 24S-hydroxycholesterol could be related
to a lower efficiency of hepatic catabolism, given that metabolics precursors in subjects with genetic hypercholesterolemia negative
d atherosclerosis, J. Steroid Biochem. Mol. Biol. (2016), http://dx.doi.
Fig. 1. Distribution of 24S-hydroxycholesterol, 27-hydroxycholesterol, desmosterol and lanosterol in non-HF GH subjects and in control population.
Table 5
Clinical characteristics of non-FH GH subjects with values of oxysterols above and below the 95th percentile of the control population.*





N 135 65 165 35
Female, n (%) 47 (52.2) 56 (50.9) 0.958 92 (57.5) 15 (37.5) 0.001
Age, years 46.1  11.6 42.8  11.6 0.098 45.6  11.7 40.5  11.2 0.056
Body Mass Index, kg/m2 25.8  3.5 24.2  3.3 0.025 25.3  3.5 24.8  3.3 0.123
LDL Cholesterol, mg/dL 216  42 209  42 0.216 214  41 212  48 0.392
Triglycerides, mg/dL 110  41 106  32 0.865 108  39 120  31 0.263
HDL Cholesterol, mg/dL 59  16 57  17 0.276 59  16 56  18 0.348
HDL Non cholesterol, mg/dL 239  43 231  43 0.251 236  42 235  48 0.381
Apolipoprotein A1, mg/dL 162  32 162  35 0.614 162  33 158  33 0.541
Apolipoprotein B, mg/dL 153  26 143  25 0.032 150  31 151  22 0.238
Mean common carotid IMT, mm 0.684  0.115 0.726  0.235 0.026 0.691  0.159 0.701  0.099 0.909
Mean carotid IMT, mm 0.745  0.139 0.762  0.203 0.243 0.751  0.163 0.722  0.103 0.201
Desmosterol to-TC  103 1.95 (1.67–2.48) 3.89 (3.27–4.45) <0.001 2.11 (1.77–3.12) 4.38 (3.84–5.20) <0.001
Lanosterol-to-TC  104 0.962 (0.732–1.16) 1.98 (1.60–2.35) <0.001 1.05 (0.78–1.56) 2.31 (1.74–2.83) <0.001
27-hydroxycholesterol to-TC  104 0.433 (0.331–0.571) 0.830 (0.682–1.02) <0.001 – –







0.072 (0.0450.110) 0.163 (0.1070.221) <0.001 0.082 (0.0530.14) 0.176 (0.1210.239) <0.001
*Values are mean  SD or median (interquartile range). #P refers to differences calculated by Student’s t-test for data normally distributed and Mann–Whitney U test for
skewed data.
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lesterol levels in human serum [37].
Increased cholesterol synthesis is frequently seen in subjects
with obesity and type 2 diabetes [38]. Actually, hepatic overpro-
duction of cholesterol is one of the mechanisms responsible for
dyslipidemia in these conditions [39,40]. The association between
body mass index and cholesterol synthesis was clearly observed in
our control population, hence confirming previous reports.
Interestingly, patients with non-FH GH have higher cholesterol
synthesis markers. However, this association was unrelated to BMI,
in contrast with the control population (supplemental figure). This
confirms that cholesterol synthesis overproduction is a primary
defect in non-FH GH [41]. Oxysterols correlate with cholesterol
synthesis markers, and therefore we speculate that subjects with
non-FH GH show high levels of oxysterols in response to hepatic
overproduction of cholesterol. The enzymes involved in hepatic
metabolism of 24S-hydroxycholesterol have not been fully defined
and it has been suggested that they are less effective than those
involved in the metabolism of other oxysterols [42], and this could
explain the higher 24S-hydroxycholesterol levels observed in our
study.
An increased synthesis of bile acids could be a compensatory
mechanism in presence of cholesterol accumulation in the liver
[43]. However, in our study there was a weak correlation between
cholesterol and oxysterols in non-FH GH subjects. Therefore, the
increase in oxysterol is not simply explained for hepatic cholesterol
accumulation.
Involvement of bile acid synthesis in the pathogenesis of non-
FH GH is supported by genetic studies revealing significant
associations between human blood sterols and variants in genes
encoding enzymes or proteins that are known to be involved in the
homeostasis of cholesterol. Genetic variants in CYP27A1, which
encodes for sterol 27-hydroxylase [44], in CYP39A1, which encodes
7a-hydroxylase [45], and in EPHX2 [46], which encodes for
epoxide hydrolase, have been associated with both oxysterol and
cholesterol concentrations. Furthermore, as mentioned ahead, a
kindred with three homozygous subjects for a loss-of-function
mutation in CYP7A1 express a phenotype compatible with FH, “in
vivo” demonstration of the importance in cholesterol homeostasis
and raising the possibility that other genetic defects in bile acid
metabolism could predispose to non-FH GH. Although bile acid
synthesis precursors were higher in cases than in controls, their
distribution do not support a severe monogenic defect because no
extreme values of oxysterol were found in non-FH GH subjects.
Therefore, if genetic variation is responsible of the high oxysterol
levels observed in our study, it could be more easily explained by
polygenic variations with minor effects than by monogenic major
effects.
24S-hydroxycholesterol has been associated with carotid
atherosclerosis in our non-FH GH population, even after adjusting
for other major risk factors of atherosclerosis. In our previous
publication, we described that in familial combined hyperlipid-
emia, a genetic hypercholesterolemia with high cardiovascular
risk, subjects with low 27-hydroxycholesterol concentrations have
increased maximum cIMT and mean cIMT [47]. If oxysterols are
involved directly in the production of atherosclerosis, or if they are
simply a passive outstand would need a further investigation.
However, there are some evidences linking oxysterols with
atherosclerosis: increased oxysterol concentrations in plasma
and arterial wall are associated with elevated superoxide anion
production in aortic tissue [48]; oxysterols promote inflammatory
response in the arterial wall [49]; the oxysterol concentration in
atherosclerotic vascular plaques relates with the severity of the
lesions [50]; and oxysterols are elevated in plasma and arteries
from patients with severe peripheral artery disease [51]. However
no association between plasma 27-hydroxycholesterol levels andPlease cite this article in press as: L. Baila-Rueda, et al., Bile acid synthesi
for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and caroti
org/10.1016/j.jsbmb.2016.10.003coronary disease was observed in a large prospective study [52].
Babiker et al. found that in subjects with advanced atherosclerosis
increased 27-oxygenated steroids were found and may reflect an
activated antiatherogenic defense mechanism, although other
explanation cannot be excluded [53].
Our study has several limitations. First, we have analyzed a
small number of oxysterols in the complex metabolic pathways of
bile acid synthesis, and these concentrations do not reflect the full
spectrum of their metabolism. Second, this study had a cross-
sectional design, and causality can not be inferred from our
atherosclerosis results due to the lack of prospective follow-up.
Third, ultrasonographic evaluation of carotid intima media
thickness is a debatable atherosclerosis subrogate in clinical
practice.
5. Conclusion
In this large cohort of patients with primary hypercholesterol-
emia of genetic origin, negative for mutations in candidate genes
for FH, plasma concentrations of oxysterols are increased in a large
proportion of cases, associated with increased cholesterol synthe-
sis. After adjusting for total cholesterol, only 24S-hydroxycholes-
terol showed increased concentration, suggesting a hepatic
catabolic defect in some non-FH GH subjects. Those patients with
the highest levels of 24S-hydroxycholesterol associated more
carotid intima media thickness. These results suggest that bile acid
metabolism is involved in the pathogenesis of some patients with
non-FH GH, and may confer a higher cardiovascular risk.
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